Research Paper Volume 16, Issue 19 pp 12769—12780
Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling
Figure 5. Bezafibrate suppressed myocardial apoptosis after CME induction. The levels of myocardial apoptosis were assayed using the TUNEL assay (n=12, **, p<0.01 vs. control group; #, ##, p<0.05, 0.01 vs. CME group).